Pennsylvania lawmakers have convened another hearing on marijuana legalization issues—this time focusing on the industry perspective, with multiple stakeholders from cannabis growing, dispensing and testing businesses, as well as clinical registrants, testifying.
Members of the House Health Subcommittee on Health Care took up cannabis policy reform at Monday’s meeting, which marked the panel’s third hearing centered on marijuana legalization in recent months.
Representatives of multi-state operators such as Cresco Labs, Trulieve, PharmaCann and INSA participated in the discussion. They advised lawmakers about regulatory considerations, including the need to balance equity with expediency in the legalization rollout as well as concerns about local opt-out rules.
“From the outset, my personal goals for adult-use has been to put health and safety of our constituents first and to allow for equitable and meaningful opportunities, particularly for those harmed by the war on drugs,” Rep. Dan Frankel (D), chair of the full Health Committee who previously sponsored cannabis legalization legislation, said at the beginning of the hearing.
“We’re still in the infancy of cannabis legislation. And there’s great uncertainty about how future federal actions might affect state markets, but we know that they will,” he said. “We want to establish a market that is sustainable
Read full article on Marijuana Moment
